OT-101

Phase 3Small molecule

OOncotelic Inc.

OT-101 is one of 131 small molecule programs targeting Myopia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

130

Competitors

Pipeline

Status by Indication[3][1]

Indication

MyopiaActive, not recruiting

Malignant Pleural MesotheliomaActive, not recruiting

Pancreatic CancerActive, not recruiting

COVID-19Active, not recruiting

MyopiaPhase 3

Active, not recruiting

Malignant Pleural MesotheliomaPhase 2

Active, not recruiting

Pancreatic CancerPhase 2/Phase 3

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

OT-101

OOncotelic Inc.

Phase 3

1 2

Bnt162b2

BioNTech

Preclinical

29 3

COVID-19 Vaccine

Moderna

Preclinical

27 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 7

Benadryl

PParkedale

Preclinical

1 8

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

3 9

Glucocorticoid

AbbVie

Preclinical

1 10

Nadroparin

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Myopia

NCT04770610

Phase 2/3Recruiting

Pancreatic Cancer

NCT06079346

Q4 2029

Phase 2Not yet recruiting

Malignant Pleural Mesothelioma

NCT05425576

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

Recruiting·OOncotelic Inc.·Phase 2/3·NCT06079346·455 enrolled

Malignant Pleural Mesothelioma1 trial

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

Not yet recruiting·OOncotelic Inc.·Phase 2·NCT05425576·63 enrolled

Myopia1 trial

Study of OT-101 in Treating Myopia

Active, not recruiting·OOcumension (Hong Kong) Limited·Phase 3·NCT04770610·678 enrolled

COVID-191 trial

A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects

Unknown status·OOncotelic Inc.·Phase 2·NCT04801017·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for OT-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OT-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OT-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oncotelic Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: OOncotelic Inc.

OT-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2029

Trials by Indication[1]

Pancreatic Cancer1 trial

Malignant Pleural Mesothelioma1 trial

Myopia1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News